-
Mashup Score: 12Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to - 8 month(s) ago
STRUCTURED ABSTRACT Background SGLT-2 inhibitors are guideline-recommended in the management of heart failure(HF). While these therapies can be initiated even in patients with comorbid CKD, some pa…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 4Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial - 11 month(s) ago
AbstractAims. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced o
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
🔥 #DELIVER 🍀#Dapa ⬇️ 32% new initiation of loop-diuretics in #HFmrEF & #HFpEF ❤️🔥 #Dapa reduced the mean dose of loop-douretic when compared to placebo 👌 Not bad as diuretic effect 🚀 @gcfmd @nephondemand @gbiondizoccai @JavedButler1 @mvaduganathan https://t.co/2TkXu1Y1Cn https://t.co/LzDypqyeb3
-
-
Mashup Score: 2Dapagliflozin and Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction - 1 year(s) ago
This pooled analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) and Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trials investigates the effect of dapagliflozin on specific causes of…
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#DAPA_POOLED 🔥 #dapa effect on Cause-Specific Mortality in #HeartFailure across the spectrum of #LVEF 🍀Significant ⬇️ of #CV_☠️ & of #All_cause-☠️ 🍀 Trend of ⬇️ #SCD ☠️ ✅ Confirmed different cause of ☠️ in #HFrEF vs #HFpEF @mmamas1973 @JavedButler1 https://t.co/oQ9bWVChVP https://t.co/mGH4M4Ab9I
-
-
Mashup Score: 2Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction - 1 year(s) ago
This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates if the effects of dapagliflozin on cardiovascular events vary with baseline kidney function.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
#DELIVER 🔥 #Dapa efficacy in #HFmrEF & #HFpEF across the full spectrum of renal function 🧩 Another piece of the puzzlereinforcing the recent metanalysis on #SGLT2i on kidney function @mvaduganathan @BrighamResearch @gcfmd @KardiologieHH @DrMarthaGulati https://t.co/UvhNzEFbP1 https://t.co/hOoiIWQRWt
-
-
Mashup Score: 17Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
Abstract Background Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. Objectives The purpose of this study was to investigate clinical outcomes…
Categories: Cardiologists, Latest HeadlinesTweet-
#DELIVER 🔥 The consistent benefit of #dapa in pts recently (<_ 30 days) hospitalized for #HeartFailure #HFmrEF #HFpEF Even here “the sooner the better” 🍀 https://t.co/2o0PJRzezX @JJheart_doc @DrNasrien @PSJhund @mvaduganathan @DrMarthaGulati @mmamas1973 @gbiondizoccai @gcfmd https://t.co/FhveNcdLRC
-
-
Mashup Score: 2Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: - 2 year(s) ago
Abstract Background Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. Objectives The purpose of this study was to investigate clinical outcomes…
Categories: Cardiologists, Latest HeadlinesTweet-
👆 #DELIVER 🔥 The consistent benefit of #dapa in pts recently (<_ 30 days) hospitalized for #HeartFailure #HFmrEF #HFpEF 👉 “Don’t delay start today” 👉 Not only major outcome but also #QoL 🍀 https://t.co/TAae2nJm8J @JACCJournals @nephondemand @MicheleSenni @morley_karina https://t.co/y3eMOkQqt4
-
-
Mashup Score: 2
Abstract Objectives This study aimed to assess the prognostic importance of hyponatremia and the effects of dapagliflozin on serum sodium in the DAPA-HF (Dapagliflozin And Prevention of Adverse out…
Source: JACC: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet-
#Dapagliflozin confers consistent benefits on mortality, worsening HF and symptoms regardless of baseline Na+ levels in ambulatory pts with #HFrEF, and reduced long-term risk of hypoNa+ (Insight from the #DAPA-HF Trial) https://t.co/CTXyCbfQiV @JACCJournals #JACCHF #Flozinators https://t.co/V3EEZ9NPhD
-
-
Mashup Score: 2Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial - 3 year(s) ago
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial is a landmark study that, along with a rapidly growing body of evidence, has firmly established SGLT2 inhibition as new standard of care for people with type 2 diabetes and chronic kidney disease.1,2 DAPA-CKD investigated dapagliflozin versus placebo in participants who had chronic kidney disease with…
Categories: Endocrinology, Latest HeadlinesTweet-
Forecasting therapeutic responses by #albuminuria and #eGFR slope during the #DAPA-CKD trial https://t.co/ysuWDoeuG0 #CKD #T2D #dapagliflozin
-
-
Mashup Score: 6
Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney disease compared with placebo. The mean difference in eGFR slope between patients treated with dapagliflozin versus placebo was greater in patients with type 2 diabetes, higher HbA1c, and higher UACR.
Categories: Endocrinology, Latest HeadlinesTweet-
Read Linked Paper 1: Effect of #dapagliflozin on the rate of decline in #kidney function in patients with chronic kidney disease with and without type 2 #diabetes: a prespecified analysis from the #DAPA-CKD trial https://t.co/ENdP2ZJgQ2 #CKD #T2D #eGFR
-
-
Mashup Score: 4
In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced albuminuria, with a larger relative reduction in patients with type 2 diabetes. The similar effects of dapagliflozin on clinical outcomes in patients with or without type 2 diabetes, but different effects on UACR, suggest that part of the protective effect of dapagliflozin in patients…
Categories: Endocrinology, Latest HeadlinesTweet-
Read Linked Paper 2: Effect of #dapagliflozin on urinary #albumin excretion in patients with chronic #kidney disease with and without type 2 #diabetes: a prespecified analysis from the #DAPA-CKD trial https://t.co/0M2AqqLniV #CKD #T2D #albuminuria
-
#ESCCongress #JACC LBCT SimPub: New from #DAPA-HF & #DELIVER: Benefit-to-risk ratio may favor continuation of #SGLT2i dapagliflozin in #HeartFailure pts w/ deterioration in kidney function to eGFR<25ml/min/1.73m2 https://t.co/3EF3ILm9fR @safchat @mvaduganathan @scottsolomon https://t.co/AdhogqJ4Ik